Study on Risk Factors and Prevention of Pre-eclampsia in Women Undergoing Assisted Reproductive Technology Including PCOS and Oocyte Recipients

What this Trial Is About

Researchers are investigating pre-eclampsia PE in women at high risk following assisted reproductive technology ART, focusing on patients with polycystic ovary syndrome PCOS and oocyte recipients. The study aims to better understand the causes and risk factors of PE to improve prenatal care and find new prevention methods. The project is divided into work packages that study maternal characteristics before pregnancy, pregnancy screening and monitoring, and placental molecular pathways at delivery. The study involves detailed assessments including blood collection, endometrial biopsy, ultrasound, and urine sampling. Participants will undergo a MOCK frozen embryo transfer preparative cycle with hormone treatments and sample collections. During pregnancy, patients will be screened for PE risk using the Fetal Medicine Foundation first trimester screening, and aspirin may be advised for those at high risk. Follow-up visits occur at several points during pregnancy, and biological samples are collected at delivery for research. Participants will be involved in various tests such as blood pressure monitoring, cardiac and nutritional evaluations, ultrasounds, and questionnaires from preconception through pregnancy and delivery. Researchers will measure a wide range of outcomes including PE incidence and severity, fetal growth, gene expression in placental tissues, and cardiovascular parameters. The study spans from preconception through delivery and includes extensive clinical and molecular data collection to understand PE development in high-risk ART patients.

At High-risk for Pre-eclampsia After Assisted Reproductive Technology